Company Focus
Merck KGaA
Latest Merck KGaA News
Biotechnology
Merck KGaA has appointed Miguel Fernández Alcalde as president of its US biopharmaceutical business, EMD Serono. 11 December 2024
Related News
Insights
Company Spotlight
A biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates.
Latest News & Features of interest to Merck KGaA
Pharmaceutical
The market for artificial intelligence (AI) in cancer care is projected to grow from $2.2 billion in 2024 to $6.3 billion by 2029, reflecting a growth rate of 23.1%, according to a recent study by BCC Research. 31 December 2024
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Imdyllytra (tarlatamab) for the treatment of adult patients with small cell lung cancer (SCLC) that has spread throughout the lungs and/or to other parts of the body. 31 December 2024
Pharmaceutical
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Winrevair (sotatercept) to treat pulmonary arterial hypertension (PAH), from US pharma giant Merck & Co. 31 December 2024
Pharmaceutical
US CNS specialist Axsome Therapeutics yesterday announced the completion of its Phase III clinical program evaluating AXS-05 (dextromethorphan-bupropion). 31 December 2024
Biotechnology
China-based biotech Duality Biologics (DualityBio) yesterday revealed that Sino-American BeiGene has exercised its exclusive option for the B7H4 antibody-drug conjugate (ADC) DB1312/BG-C9074. 31 December 2024
Pharmaceutical
China’s National Medical Products Administration (NMPA) has recently approved Zorifer (zorifertinib), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) specifically for the treatment of non-small cell lung cancer (NSCLC) with CNS metastases. 30 December 2024
Biotechnology
Johnson & Johnson has secured European approval for Rybrevant (amivantamab) in combination with Lazcluze (lazertinib), as a first-line treatment for certain patients with non-small cell lung cancer (NSCLC). 30 December 2024
Biotechnology
Antibody-drug conjugates (ADCs) combine monoclonal antibody (MAb) specificity with cytotoxic drug potency via a linker, delivering targeted cancer therapy. ADCs concentrate treatment at tumor sites, enhancing efficacy while minimizing harm to healthy tissues. 30 December 2024
Biotechnology
Japanese drugmaker Daiichi Sankyo revealed on Friday that its Datroway (datopotamab deruxtecan; dato-dxd) has been approved in Japan for the treatment of adult patients with hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) unresectable or recurrent breast cancer after prior chemotherapy. 30 December 2024
Biotechnology
Dutch immunology specialist argenx announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) approved Vyvdura (efgartigimod alfa and hyaluronidase-qvf) for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 30 December 2024
Latest In Brief for Merck KGaA
Biotechnology
TJ Bio has reportedly submitted a biologics license application (BLA) to China’s Center for Drug Evaluation for GX-H9 (eftansomatropin alfa), a second-generation therapy for pediatric growth hormone deficiency. 31 December 2024
Latest Relevant Ones To Watch News
Privately-held immunotherapy company Inmagene Biopharmaceuticals is taking over Ikena Oncology in a reverse merger deal, forming a new company, InmageneBio. 27 December 2024
17 December 2024
12 December 2024
5 December 2024
3 December 2024
29 November 2024
26 November 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze